Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 70 Carcinoma, Hepatocellular 25 Prostatic Neoplasms 21 Neoplasm Metastasis 19 Neoplasms 17 Carcinoma, Non-Small-Cell Lung 16 Kidney Neoplasms 14 Osteosarcoma 9 Neuroendocrine Tumors 9 Carcinoma, Transitional Cell 9 Carcinoma, Medullary 9 Sarcoma 8 Colorectal Neoplasms 8 Urinary Bladder Neoplasms 7 Sarcoma, Ewing 7 Melanoma 7 Breast Neoplasms 7 Brain Neoplasms 7 Thyroid Neoplasms 6 Ovarian Neoplasms 6 Clear-cell metastatic renal cell carcinoma 6 Recurrence 5 Pancreatic Neoplasms 5 Lung Neoplasms 5 Carcinoma 5 Urethral Neoplasms 4 Triple Negative Breast Neoplasms 4 Multiple Myeloma 4 Liver Neoplasms 4 Thyroid Cancer, Papillary 3

Interventions

mirdametinib 3 Imatinib Mesylate 3 Surveys and Questionnaires 2 tipifarnib 1 talimogene laherparepvec 1 pirfenidone 1 nilotinib 1 emvododstat 1 diphenylcyclopropenone 1 cabozantinib 1 binimetinib 1 Sunitinib 1 Sirolimus 1 Sevoflurane 1 Propofol 1 Percutaneous Collagen Induction 1 Nitrous Oxide 1 Magnetic Resonance Spectroscopy 1 Lidocaine 1 Lasers, Solid-State 1 Lasers 1 Glycopyrrolate 1 Dexmedetomidine 1 Blood Specimen Collection 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatoses × cabozantinib × Clear all

NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed

45 enrolled 10 charts

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡